Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 15,650 shares at $23.88 ($379K) on 2021-07-01, disclosed to the SEC on 2021-07-02.
Open-market sale of $379k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.88 | 4,350 | $104K | 27.4% |
| 2 | $24.35 | 5,650 | $138K | 36.3% |
| 3 | $24.35 | 5,650 | $138K | 36.3% |
| Total | $24.22 avg | 15,650 | $379K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |